Last reviewed · How we verify
Topical TA
Topical TA (triamcinolone acetonide) is a corticosteroid that suppresses local inflammatory and immune responses when applied to the skin.
Topical TA (triamcinolone acetonide) is a corticosteroid that suppresses local inflammatory and immune responses when applied to the skin. Used for Inflammatory and pruritic dermatological conditions (e.g., eczema, psoriasis, dermatitis), Localized skin inflammation and allergic reactions.
At a glance
| Generic name | Topical TA |
|---|---|
| Also known as | Active comparator |
| Sponsor | Aswan University Hospital |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Triamcinolone acetonide binds to glucocorticoid receptors in skin cells, reducing the production of inflammatory cytokines and mediators. This leads to decreased inflammation, itching, and immune cell infiltration at the site of application. It is used for localized dermatological conditions where anti-inflammatory and immunosuppressive effects are therapeutically beneficial.
Approved indications
- Inflammatory and pruritic dermatological conditions (e.g., eczema, psoriasis, dermatitis)
- Localized skin inflammation and allergic reactions
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Folliculitis
Key clinical trials
- Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis (PHASE3)
- Effectiveness of Periocular Drug Injection in CATaract Surgery (PHASE3)
- Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma (PHASE2)
- Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia (PHASE1)
- Tranexamic Acid in Pregnant Women Undergoing Cesarean Section. (NA)
- Topical Tranexamic Acid Application in Rhinoplasty (PHASE4)
- Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease (PHASE1)
- Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical TA CI brief — competitive landscape report
- Topical TA updates RSS · CI watch RSS
- Aswan University Hospital portfolio CI